Market Cap: $1.5 billion | Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products.
On May 1, 2018, Sarissa Capital Management, starting with a 2.4% stake, filed proxy materials to elect its nominee as a Class II director, coinciding with the company's announcement of its intent to split into two independent publicly traded firms.
On May 31, 2018, shareholders reelected all three incumbent directors at the AGM, and Sarissa endorsed Ironwood’s leadership in pursuing the split, refraining from seeking a board seat.
On May 16, 2019, with a 6.1% stake, Sarissa praised the spinoff of the company's R&D business as a good first step towards enhancing shareholder value. Source
On February 26, 2020, Sarissa increased its stake to 7.9%.
On November 5, 2020, Alexander J. Denner, Ph.D., Sarissa's founder and CIO, was appointed to the board. Source
On March 1, 2021, Sarissa further increased its stake to 9.3%.
コメント